101 related articles for article (PubMed ID: 6881973)
1. [Phase I study of Bestatin: (I) A clinical study on determination of an optimal dose of Bestatin].
Saito K; Miyasato H; Tajima K; Ikeda S
Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt):211-7. PubMed ID: 6881973
[TBL] [Abstract][Full Text] [Related]
2. [A new antitumor drug with immunomodulating activity, ubenimex (bestatin)].
Tsukagoshi S
Gan To Kagaku Ryoho; 1987 Jul; 14(7):2385-91. PubMed ID: 3496857
[TBL] [Abstract][Full Text] [Related]
3. [Phase III controlled studies of bestatin in malignant tumors of the skin--results of treatment of squamous cell carcinoma and genital Paget's disease].
Ikeda S; Ishihara K; Taguchi G
Gan To Kagaku Ryoho; 1985 Jun; 12(6):1260-6. PubMed ID: 2988457
[TBL] [Abstract][Full Text] [Related]
4. [Phase III study of bestatin in patients with malignant skin tumors. (1) Malignant melanoma].
Ikeda S; Ishihara K; Taguchi G
Gan To Kagaku Ryoho; 1985 Jan; 12(1):77-85. PubMed ID: 3881086
[TBL] [Abstract][Full Text] [Related]
5. Partial review of immunotherapeutic pharmacology in stem cell transplantation.
Bierman PJ; Abe F; Buyukberber S; Ino K; Talmadge JE
In Vivo; 2000; 14(1):221-36. PubMed ID: 10757081
[TBL] [Abstract][Full Text] [Related]
6. [Phase I study of forphenicinol, a new biological response modifier].
Terakado T; Saito K; Tajima K; Miyasato H; Suzuki T; Ikeda S
Gan To Kagaku Ryoho; 1983 Nov; 10(11):2309-17. PubMed ID: 6639093
[TBL] [Abstract][Full Text] [Related]
7. Immunopotentiation in infectious disease, I. Effect of bestatin on the immune response.
Ormrod DJ; Cawley S; Miller TE
Chemioterapia; 1985 Aug; 4(4):313-23. PubMed ID: 3876888
[TBL] [Abstract][Full Text] [Related]
8. Changes of the blood lymphocyte population in cancer patients treated with bestatin, a new immunomodulator. A phase I study.
Blomgren H; Strender LE; Edsmyr F
Biomedicine; 1980 Dec; 32(4):178-85. PubMed ID: 7470579
[TBL] [Abstract][Full Text] [Related]
9. The effect of bestatin on patients with acute and chronic leukemia and malignant lymphoma.
Arimori S; Nagao T; Shimizu Y; Watanabe K; Komatsuda M
Tokai J Exp Clin Med; 1980 Jan; 5(1):63-71. PubMed ID: 6930119
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant therapy with 5-fluoro-1-(2-tetrahydrofuryl)-2,4 (1H,3H)-pyrimidinedione (UFT) and Bestatin in patients with transitional cell carcinoma of the bladder--comparison between UFT therapy alone and UFT therapy in combination with Bestatin.
Uchibayashi T; Kunimi K; Yamamoto H; Koshida K
Int J Clin Pharmacol Ther; 1995 Aug; 33(8):465-8. PubMed ID: 8556228
[TBL] [Abstract][Full Text] [Related]
11. [Experimental and clinical studies of bestatin as an immunomodulator].
Miwa H; Oka T; Tsurumi T; Sakae Y; Orita K
Gan To Kagaku Ryoho; 1982 Jul; 9(6):1019-24. PubMed ID: 7184437
[TBL] [Abstract][Full Text] [Related]
12. [The immunomodulating action of bestatin in the combined therapy of bladder cancer patients].
Neprina GS; Panteleeva ES; Vatin OE; Kariakin OB
Urol Nefrol (Mosk); 1994; (2):34-8. PubMed ID: 8017004
[TBL] [Abstract][Full Text] [Related]
13. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T
Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102
[TBL] [Abstract][Full Text] [Related]
14. Influence of Bestatin, a new immunomodulator, on various functions of human monocytes.
Jarstrand C; Blomgren H
J Clin Lab Immunol; 1982 Dec; 9(3):193-8. PubMed ID: 7166751
[TBL] [Abstract][Full Text] [Related]
15. [Clinical studies of bestatin on genitourinary cancer].
Ichikawa T; Hirokawa I; Ishihara Y
Jpn J Antibiot; 1985 Jan; 38(1):166-78. PubMed ID: 3989976
[TBL] [Abstract][Full Text] [Related]
16. Low molecular weight immunomodifiers produced by microorganisms.
Umezawa H; Ishizuka M
Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23 Suppl 1():S9-13. PubMed ID: 3842696
[TBL] [Abstract][Full Text] [Related]
17. [Bestatin therapy of chronic myelogenous leukemia].
Uzuka Y; Saito Y
Gan To Kagaku Ryoho; 1993 Feb; 20(2):207-14. PubMed ID: 8434958
[TBL] [Abstract][Full Text] [Related]
18. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
[TBL] [Abstract][Full Text] [Related]
19. A review of clinical studies of bestatin.
Oka S
Recent Results Cancer Res; 1980; 75():126-32. PubMed ID: 7015425
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulating properties of bestatin in cancer patients. A phase II trial.
Mathé G; Umezawa H; Misset JL; Brienza S; Canon C; Musset M; Reizenstein P
Biomed Pharmacother; 1986; 40(10):379-82. PubMed ID: 3495299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
